Medtronic has announced US Food and Drug Administration (FDA) 510(k) clearance of the Accurian RF ablation platform, which conducts radio frequency (RF) ablation of nerve tissues.
RF ablation is a minimally invasive procedure in which current produced by radio waves heats up a small area of nerve tissue to stop it from sending pain signals, thereby reducing pain. The Accurian system combines proprietary hardware and quad core processing with advanced software for power and temperature control resulting in consistent and predictable lesion formation. It also offers independent channel management and advanced smart features that may support procedural efficiency.
“The Accurian RF ablation platform is a significant addition in my practice because I know I’ll get the same lesion every time in every channel due to how responsive the generator is in managing power and temperature,” said Leo Kapural, a pain physician at Carolinas Pain Institute and Center for Clinical Research in Winston-Salem, USA. “RF ablation requires both precision and flexibility. Accurian is intuitive and easy to use and enables me to easily upgrade the system and perform enhanced lesions with cooled RF probes.”
The Accurian RF ablation platform can perform standard, pulsed, and enhanced procedures using internally-cooled probes to create a comprehensive range of lesion shapes, sizes, and volumes. It has independent channel control and chip-enhanced probes for easy on-screen identification, as well as smart features, such as downloadable procedure reports to support ease of use and efficiency. The Accurian system has been extensively tested for lasting reliability and is upgrade-ready as technology advances.